265 related articles for article (PubMed ID: 30333869)
21. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
[TBL] [Abstract][Full Text] [Related]
22. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
24. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
25. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.
Meng F; Wang F; Wang L; Wong SC; Cho WC; Chan LW
Front Genet; 2016; 7():197. PubMed ID: 27895663
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
27. The IGF-1R Inhibitor NVP-AEW541 Causes Insulin-Independent and Reversible Cardiac Contractile Dysfunction.
Schenkl C; Schrepper A; Heyne E; Doenst T; Schwarzer M
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009569
[TBL] [Abstract][Full Text] [Related]
28. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
Tsushima H; Morimoto S; Fujishiro M; Yoshida Y; Hayakawa K; Hirai T; Miyashita T; Ikeda K; Yamaji K; Takamori K; Takasaki Y; Sekigawa I; Tamura N
Autoimmunity; 2017 Aug; 50(5):329-335. PubMed ID: 28682648
[TBL] [Abstract][Full Text] [Related]
29. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
31. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
[TBL] [Abstract][Full Text] [Related]
32. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
[TBL] [Abstract][Full Text] [Related]
33. Tanshinone IIA Attenuates Insulin Like Growth Factor 1 -Induced Cell Proliferation in PC12 Cells through the PI3K/Akt and MEK/ERK Pathways.
Wang H; Su X; Fang J; Xin X; Zhao X; Gaur U; Wen Q; Xu J; Little PJ; Zheng W
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213025
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
35. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Premkumar DR; Jane EP; Pollack IF
Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
[TBL] [Abstract][Full Text] [Related]
36. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
37. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
[TBL] [Abstract][Full Text] [Related]
38. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
40. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
